DNB:EURONEXT OSLODNB Bank ASA Analysis
Data as of 2026-03-10 - not real-time
$30.07
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
DNB shares are trading at $30.07, comfortably above the 200‑day SMA (28.04) but below the 20‑day and 50‑day SMAs (31.86 and 30.12), indicating a short‑term pullback within a longer‑term bullish framework. The stock sits near its technical support at $29.52 and faces resistance around $33.50, while the MACD histogram is negative and the signal line is bearish, suggesting modest downside pressure in the near term. Valuation metrics are compelling: the forward‑looking DCF fair value is $56.50, more than 80% above the current price, and the trailing P/E of 10.2 is well below the industry average of 17.3, flagging significant undervaluation. A dividend yield of 6.17% with a payout ratio of 59% adds income appeal, and the beta of roughly 0.2 points to low market sensitivity. Fundamentally, DNB delivers strong profitability with a 49.6% net margin, 59% operating margin, and a 15% ROE, supported by robust cash balances of $563 bn against debt of $1.37 tn. The combination of solid earnings, attractive yield, and a substantial valuation gap positions the stock as a compelling value play in a low‑volatility, stable Norwegian banking environment.
While short‑term technical signals are mixed, the medium‑ to long‑term outlook remains positive, driven by the bank’s high dividend sustainability, strong capital generation, and the market’s current “Extreme Greed” sentiment which may be overstating near‑term risk. The relatively low 30‑day volatility of 39.5% and modest max drawdown of 22% further support a measured risk profile, making DNB a suitable candidate for investors seeking income and upside potential.
While short‑term technical signals are mixed, the medium‑ to long‑term outlook remains positive, driven by the bank’s high dividend sustainability, strong capital generation, and the market’s current “Extreme Greed” sentiment which may be overstating near‑term risk. The relatively low 30‑day volatility of 39.5% and modest max drawdown of 22% further support a measured risk profile, making DNB a suitable candidate for investors seeking income and upside potential.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price hovering just above technical support at $29.52
- Bearish MACD histogram indicating near‑term downside
- High dividend yield providing cushion
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant valuation gap (DCF fair value $56.5 vs current $30.07)
- Strong profitability and ROE of 15%
- Attractive dividend yield with sustainable payout
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Consistently low beta (~0.2) indicating stability
- Robust cash generation and solid capital base
- Undervalued relative to peers with room for price appreciation
Key Metrics & Analysis
Financial Health
Revenue Growth5.30%
Profit Margin49.56%
P/E Ratio10.2
ROE15.02%
ROA1.19%
P/B Ratio1.6
Op. Cash Flow$72.6B
Industry P/E17.3
Technical Analysis
TrendBullish
RSI43.6
Support$29.52
Resistance$33.50
MA 20$31.86
MA 50$30.12
MA 200$28.04
MACDBearish
VolumeStable
Fear & Greed Index76.91
Valuation
Fair Value$56.50
GradeUndervalued
TypeValue
Dividend Yield6.17%
Risk Assessment
Beta0.20
Volatility39.54%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.